Outlook Therapeutics announced that at a Special Meeting on July 16, 2026, its stockholders approved several key proposals. These include a significant increase in the number of authorized shares of common stock and granting the Board of Directors authority to effect a reverse stock split.
Key Details
- Authorized Share Increase: Stockholders approved an amendment to the company's Certificate of Incorporation to increase the total number of authorized shares of common stock from 260,000,000 to 600,000,000. This amendment was filed and became effective on July 16, 2026.
- Reverse Stock Split Authority: The Board of Directors has been granted the authority to effect a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-50, to be determined at the Board's discretion.
- Warrant-Related Issuances: Approval was also granted for the potential issuance of common stock underlying various warrants issued in connection with an April 2026 offering.